Hello, I run a core facility for the University of Arizona and we are about to jump into next gen seq. This is my first post and I'm not sure if this is the appropriate place to ask this question but I was wondering if there was a consensus from actual researchers on which next gen platform is preferred. Any and all replies are appreciated. I'm very excited to be a part of such a great forum!
Unconfigured Ad
Collapse
X
-
Hey Ryan!
I moved your post to the general forum so it gets wider viewing.
I think for a core facility you will need 454 + either Solexa/SOLiD. The drastic differences in read length/throughput are a good complement.
As to Solexa vs. SOLiD, there isn't much to judge yet for the ABI technology...that will likely play out over the next years.
-
Thanks ECO,
I agree they are a great compliment to each other, with limited resources we are forced to pick one or the other. I have just started to see publications come out using SOLiD data and the sales reps are getting pretty pushy here at the end of Q4. Just wanted to find out if anybody had serious problems with either platform. Thanks again, by the way loved the Tasmanian Devil pic!Ryan Sprissler
Staff Scientist - manager University of Arizona Genetic Core (UAGC)
Comment
-
Before jumping in you should definitely get a sense of what the PIs would get the most out of. While they are both considered next gen systems, short read and long read sequences are often very different animals as far as the applications they are used for. For example, 454 would be a waste for small RNA analysis and expression tags - but it can't be beat for metagenomics and transcriptome analysis.
While I wouldn't underestimate ABI, I think Illumina beat them for this generation of short read next gen systems
Comment
Latest Articles
Collapse
-
by SEQadmin2
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...-
Channel: Articles
07-31-2026, 11:01 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 08-24-2026, 10:32 AM
|
0 responses
28 views
0 reactions
|
Last Post
by SEQadmin2
08-24-2026, 10:32 AM
|
||
|
Started by SEQadmin2, 08-20-2026, 11:17 AM
|
0 responses
41 views
0 reactions
|
Last Post
by SEQadmin2
08-20-2026, 11:17 AM
|
||
|
Started by SEQadmin2, 08-18-2026, 10:05 AM
|
0 responses
41 views
0 reactions
|
Last Post
by SEQadmin2
08-18-2026, 10:05 AM
|
||
|
Started by SEQadmin2, 08-13-2026, 12:22 PM
|
0 responses
49 views
0 reactions
|
Last Post
by SEQadmin2
08-13-2026, 12:22 PM
|
Comment